Ostovan Vahid Reza, Tabrizi Reza, Bazrafshan Hanieh, Bahrami Zahra, Khazraei Hajar, Khazraei Samaneh, Borhani-Haghighi Afshin, Moghadami Mohsen, Grant Matthew
Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Curr Fungal Infect Rep. 2022;16(4):143-153. doi: 10.1007/s12281-022-00440-2. Epub 2022 Aug 11.
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) can increase the susceptibility of individuals to contracting mucormycosis through several mechanisms. Nowadays, coronavirus disease (COVID-19)-associated mucormycosis (CAM) is a serious public health concern, particularly in developing countries. This meta-analysis aims to identify the risk factors that affect the mortality rate of patients with CAM.
We systematically searched PubMed, Google Scholar, Scopus, Cochrane library, and preprint databases using pertinent keywords and the reference lists of the included relevant articles from inception till October 27, 2021. In order to reduce the effects of small-scale studies, we only selected cross-sectional, case-control, and cohort studies and case series with at least four patients. We identified 26 articles that included 821 patients with CAM. The effect size (ES) of mortality rate was 28% (95% confidence interval (CI) 20%-38%; I =82.28%; p for Cochran Q<0.001). The CAM patients with a history of comorbidities other than diabetes (malignancies, transplant, or renal failure), mechanical ventilation due to COVID-19, pulmonary and cerebral mucormycosis, and those who only received medical treatment for mucormycosis had the highest mortality rate.
Coronavirus disease (COVID-19)-associated mucormycosis (CAM) is a major public health problem, particularly in developing countries. Severe COVID-19 infection, history of mechanical ventilation, early CAM, comorbidities other than diabetes (malignancies, transplant, or renal failure), pulmonary and rhino-orbito-cerebral mucormycosis, and delivering only medical treatment for mucormycosis were the worst prognostic factors in CAM patients. Identifying the mortality-related risk factors in CAM patients may help reduce the mortality rate by implementing optimized treatment approaches.
The online version contains supplementary material available at 10.1007/s12281-022-00440-2.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)可通过多种机制增加个体感染毛霉菌病的易感性。如今,冠状病毒病(COVID-19)相关毛霉菌病(CAM)是一个严重的公共卫生问题,尤其是在发展中国家。本荟萃分析旨在确定影响CAM患者死亡率的危险因素。
我们使用相关关键词以及纳入的相关文章从创刊至2021年10月27日的参考文献列表,系统检索了PubMed、谷歌学术、Scopus、Cochrane图书馆和预印本数据库。为了减少小规模研究的影响,我们仅选择了横断面研究、病例对照研究、队列研究以及至少有4例患者的病例系列。我们确定了26篇文章,其中包括821例CAM患者。死亡率的效应量(ES)为28%(95%置信区间(CI)20%-38%;I² = 82.28%;Cochran Q检验的p<0.001)。有糖尿病以外合并症病史(恶性肿瘤、移植或肾衰竭)、因COVID-19进行机械通气、肺部和脑部毛霉菌病的CAM患者,以及仅接受毛霉菌病药物治疗的患者死亡率最高。
冠状病毒病(COVID-19)相关毛霉菌病(CAM)是一个主要的公共卫生问题,尤其是在发展中国家。严重的COVID-19感染、机械通气史、早期CAM、糖尿病以外的合并症(恶性肿瘤、移植或肾衰竭)、肺部和鼻眶脑毛霉菌病以及仅进行毛霉菌病药物治疗是CAM患者预后最差的因素。识别CAM患者中与死亡率相关的危险因素可能有助于通过实施优化的治疗方法降低死亡率。
在线版本包含可在10.1007/s12281-022-00440-2获取的补充材料。